|
Title
|
Publication Date
|
Price
|
Relevance
|
Obesity Drug Markets in the US and EU
Analysis of product pipelines and the competitive environment
|
Jul 2008 |
£2,425 |
100% |
|
Will Anyone Crack the Obesity Drug Market?
|
Feb 2011 |
£1,495 |
92% |
Commercial and Pipeline Perspectives: Obesity
Lack of Reimbursement Limits Market Potential
|
Dec 2006 |
£7,210 |
87% |
World Market for Cancer Therapeutics and Biotherapeutics, The
4th Edition
|
Oct 2011 |
£2,215 |
80% |
|
Torisel (Renal Cell Carcinoma) – Analysis and Forecasts to 2020
|
Oct 2011 |
£1,265 |
77% |
World Diabetes Drug Market
2011-2021
|
Mar 2011 |
£1,499 |
75% |
United Arab Emirates Pharmaceuticals and Healthcare Report Q4
2011
|
Oct 2011 |
£330 |
74% |
Commercial Insight: Osteoarthritis
Market sees steady growth
|
Dec 2006 |
£8,365 |
74% |
|
Axitinib (Renal Cell Carcinoma) – Analysis and Forecasts to 2020
|
Oct 2011 |
£1,265 |
74% |
Brivanib
Analysis and Market Forecasts from 2013 to 2020
|
Jul 2011 |
£1,265 |
74% |
The Future of GPCRs in Drug Discovery
Novel Technologies, Leading Companies, and Opportunities for Target Expansion
|
Apr 2010 |
£2,425 |
73% |
|
Afinitor (Renal Cell Carcinoma) – Analysis and Forecasts to 2020
|
Oct 2011 |
£1,265 |
73% |
|
Nexavar (Renal Cell Carcinoma) – Analysis and Forecasts to 2020
|
Oct 2011 |
£1,265 |
73% |
Global Diabetes Market Report
2011 Edition
|
Oct 2011 |
£505 |
72% |
|
Avastin (Renal Cell Carcinoma) – Analysis and Forecasts to 2020
|
Oct 2011 |
£1,265 |
72% |
|
Sleep Disorders: Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking
|
Mar 2009 |
£1,265 |
72% |
|
Cardiovascular Drugs
|
Apr 2010 |
£2,815 |
72% |
Patient Empowerment
Empowered Patients Can Change Healthcare Outcomes And Impact The Pharmaceutical Industry
|
Jul 2007 |
£3,600 |
71% |
|
World Glucose Self-Testing Markets
|
Jan 2012 |
£2,150 |
71% |
|
Votrient (Renal Cell Carcinoma) – Analysis and Forecasts to 2020
|
Oct 2011 |
£1,265 |
71% |
Stakeholder Insight: Osteoarthritis
Drug development lags behind rising osteoarthritis population
|
Dec 2009 |
£9,615 |
70% |
Miripla
Analysis and Market Forecasts from 2010 to 2020
|
Jul 2011 |
£1,265 |
69% |
|
Anti-Hypertensive Drugs
|
Feb 2010 |
£2,500 |
69% |
|
Dovitinib (Renal Cell Carcinoma) – Analysis and Forecasts to 2020
|
Oct 2011 |
£1,265 |
68% |
|
Rencarex (Renal Cell Carcinoma) – Analysis and Forecasts to 2020
|
Oct 2011 |
£1,265 |
68% |
|
Tivozanib (Renal Cell Carcinoma) – Analysis and Forecasts to 2020
|
Oct 2011 |
£1,265 |
68% |
|
Anyara (Renal Cell Carcinoma) – Analysis and Forecasts to 2020
|
Oct 2011 |
£1,265 |
68% |
|
Sutent (Renal Cell Carcinoma) – Analysis and Forecasts to 2020
|
Oct 2011 |
£1,265 |
68% |
Avastin (Liver Cancer)
Analysis and Forecasts to 2020
|
Jul 2011 |
£1,265 |
67% |
Medical Devices: Industry and Market Prospects
2010-2025
|
Oct 2010 |
£1,499 |
67% |
